Crossref
journal-article
Informa UK Limited
Future Medicinal Chemistry (301)
Authors
11
- Steffen Renner (first)
- Maxim Popov (additional)
- Ansgar Schuffenhauer (additional)
- Hans-Joerg Roth (additional)
- Werner Breitenstein (additional)
- Andreas Marzinzik (additional)
- Ian Lewis (additional)
- Philipp Krastel (additional)
- Florian Nigsch (additional)
- Jeremy Jenkins (additional)
- Edgar Jacoby (additional)
References
182
Referenced
56
-
Bartlett PA EntzerothM. Exploiting Chemical Diversity for Drug Discovery. Royal Society of Chemistry Cambridge UK (2006).
(
10.1039/9781847552556
) 10.1016/j.drudis.2006.02.001
10.2174/1568026053828376
10.1016/j.cbpa.2010.03.024
10.1002/(SICI)1097-0290(199824)61:1<61::AID-BIT11>3.0.CO;2-C
10.2174/092986709789712862
10.1016/j.bcp.2009.02.015
10.1002/(SICI)1098-1128(199601)16:1<3::AID-MED1>3.0.CO;2-6
10.1016/S1359-6446(97)01163-X
10.1002/anie.200462457
10.1021/ja902302h
10.1039/c0md00020e
10.1021/jm060217p
10.1021/jm801513z
10.1016/S0169-409X(00)00129-0
- Oprea TI , DavisAM, TeagueSJ, LeesonPD. Is there a difference between leads and drugs? A historical perspective.J. Chem. Inf. Model.41(5), 1308–1315 (2001). / J. Chem. Inf. Model. / Is there a difference between leads and drugs? A historical perspective. by Oprea TI (2001)
10.1021/jm000292e
10.1021/jm0492002
10.1038/nrd2445
10.1517/17460441003605098
10.1038/nchembio.180
10.1073/pnas.0404719101
10.1073/pnas.0503647102
10.1515/bc.2010.013
10.1038/nchembio.362
10.1038/nchem.730
10.1021/ci700286x
10.1021/ci050480j
10.1007/s11030-006-9054-0
10.1016/j.drudis.2008.10.011
10.1016/j.drudis.2009.07.014
10.1021/jm901241e
10.1021/jm1008456
10.1021/jm010934d
10.1016/j.cbpa.2010.03.020
10.1021/jm030266r
10.1021/jm030191r
10.1021/jm901137j
10.4155/fmc.10.237
10.1016/S1359-6446(04)03275-1
10.2174/138620708784911492
10.1021/ci0503558
10.1177/096032719101000405
10.1007/s10822-007-9105-3
10.1016/j.drudis.2010.08.004
10.2174/1568026054637700
10.1016/j.drudis.2007.08.005
10.1007/s10822-009-9280-5
- Hubbard RE , ChenI, DavisB. Informatics and modeling challenges in fragment-based drug discovery.Curr. Opin. Drug. Discov. Devel.10(3), 289–297 (2007). / Curr. Opin. Drug. Discov. Devel. / Informatics and modeling challenges in fragment-based drug discovery. by Hubbard RE (2007)
10.1016/j.sbi.2010.04.003
10.1038/nrd2220
10.1016/j.drudis.2009.04.007
10.1016/j.coph.2009.04.009
10.2174/156802607782341082
10.1158/0008-5472.CAN-07-5256
10.1038/nchembio.421
10.1073/pnas.89.12.5381
10.1016/j.cbpa.2010.02.017
10.1021/bc1001483
10.1126/science.287.5460.1964
10.1002/anie.200705415
10.1039/b816852k
- Galloway WR , Isidro-LlobetA, SpringDR. Diversity-oriented synthesis as a tool for the discovery of novel biologically active small molecules.Nat. Commun.1(6), (2010). / Nat. Commun. / Diversity-oriented synthesis as a tool for the discovery of novel biologically active small molecules. by Galloway WR (2010)
10.1021/jm9010687
10.1016/j.ccr.2006.08.027
10.1038/nrd2590
10.2174/156802610792232097
10.2174/092986709787002844
10.1021/ja900488a
10.1038/nrd1255
10.1210/jc.2009-2272
10.1210/jc.2008-1008
10.1088/0957-4484/21/6/065104
10.1166/jbn.2009.036
10.1038/nbt1228
10.1038/nrd2199
-
Lackey KE . Gene family targeted molecular design. John Wiley & Sons Inc. Hoboken NJ USA (2008).
(
10.1002/9780470423936
) 10.1016/S1074-5521(99)89004-8
10.1016/1047-8477(91)90048-2
10.1002/anie.200462643
10.1002/cmdc.200500008
10.1038/nchembio0709-436
10.1016/j.drudis.2009.10.010
- Sippl W JungM. Epigenetic Targets in Drug Discovery. Wiley-VCH Verlag GmbH & Co. KGaA Weinheim Germany (2009).
10.1021/ci025569t
10.1016/S0022-2836(02)00811-2
10.1016/j.jmb.2006.04.024
10.1093/nar/gkj062
10.1021/ci800289y
10.1021/ci1001263
10.1021/ci900349y
10.1002/cbic.200900604
10.1021/ci060003g
10.1021/jm060902w
10.1021/ci800023x
10.1371/journal.pcbi.1000397
10.1021/ci600300k
10.2174/138620708785739952
10.1021/ci6002043
10.1002/cmdc.200600147
10.1002/cbic.200400369
10.1002/cmdc.200700026
10.1021/ci800344p
10.1021/jm801546k
10.2174/138161209787315594
10.1021/jm00120a002
10.2174/1386207043328544
10.2174/138955707782331722
10.1016/j.cbpa.2010.02.018
10.1021/jm0502900
10.1021/ci8003896
10.1021/jm701021b
10.1093/bioinformatics/btn479
10.1021/ci600338x
10.1038/nchembio.188
10.1038/nchembio.187
10.1002/anie.200906555
10.1002/cmdc.200900419
10.1002/cmdc.201000272
10.1021/ci100203e
10.1007/s00018-009-0117-0
10.1126/science.273.5275.595
10.1093/bioinformatics/btg1086
10.1016/S0969-2126(97)00260-8
10.1093/nar/gkm993
10.1038/nbt1284
10.1038/nature08506
10.1126/science.1158140
10.1038/nrd3139
- Köppen H . Virtual screening – what does it give us?Curr. Opin. Drug Discovery Dev.12(3), 397–407 (2009). / Curr. Opin. Drug Discovery Dev. / Virtual screening – what does it give us? by Köppen H (2009)
10.1021/ja0771033
10.1006/jmbi.2001.4551
10.1021/jm8009958
10.1021/ci8003732
10.1007/s10822-010-9356-2
10.1111/j.1747-0285.2010.01041.x
10.1021/jp807701h
10.1021/jm030331x
10.1021/ci600342e
10.1021/ci900043r
10.1111/j.1747-0285.2009.00829.x
10.1023/A:1016399411208
10.1186/1758-2946-1-6
10.1007/s10822-009-9276-1
10.1016/j.drudis.2009.03.013
10.1021/ci100182c
10.1021/jm050114r
10.1021/ci700455u
10.1021/ci7004548
10.1021/ci8000265
10.1021/jm060167o
10.1021/ci7003626
10.1021/ci900199e
10.1007/s00894-008-0360-6
10.1002/qsar.200610091
10.2174/138955706778742768
- Mauser H , GubaW. Recent developments in de novo design and scaffold hopping. Curr. Opin. Drug Discovery Dev.11(3), 365–374 (2008). / Curr. Opin. Drug Discovery Dev. / Recent developments in de novo design and scaffold hopping by Mauser H (2008)
10.1002/minf.201000019
10.1002/cmdc.200500005
10.1021/jm050468i
10.1021/jm100492z
10.1002/anie.200604125
10.1021/ci700418f
10.1007/BF00124349
10.1021/ci060094h
10.1021/jm061259g
10.1002/cmdc.200800355
- InFarmatik Kft www.infarmatik.com
- Prestwick Chemical www.prestwickchemical.com
- AnalytiCon Discovery GmbH www.ac-discovery.com
- Astex Therapeutics Ltd www.astex-therapeutics.com
- Evotec AG www.evotec.com
- Vernalis plc www.vernalis.com
- Ensemble Therapeutics www.ensemblediscovery.com
- Nuevolution A/S www.nuevolution.com
- Philochem AG www.philochem.ch
- GVK-BIO. GVK Bio database suite www.gvkbio.com
- EBI ChEMBL database www.ebi.ac.uk/chembl
- ExPASy Swiss-Prot www.expasy.ch/sprot
- NCBI OMIM database www.ncbi.nlm.nih.gov/omim
- EBI InterPro database www.ebi.ac.uk/interpro
- Breitenstein W Ehrhardt C Maibaum JK et al. Aminopiperidines and their preparation pharmaceutical compositions and use in the treatment of diseases associated with renin activity such as hypertension. PCT Int. Appl. (2007) 232 pp. CODEN: PIXXD2 WO 2007006534 A2 20070118 CAN 146:163026 AN 2007:61694 CAPLUS.
Dates
Type | When |
---|---|
Created | 14 years, 3 months ago (May 9, 2011, 2:51 p.m.) |
Deposited | 1 year, 3 months ago (May 23, 2024, 3:50 p.m.) |
Indexed | 1 year, 3 months ago (May 23, 2024, 4:40 p.m.) |
Issued | 14 years, 4 months ago (April 1, 2011) |
Published | 14 years, 4 months ago (April 1, 2011) |
Published Online | 14 years, 3 months ago (May 9, 2011) |
Published Print | 14 years, 4 months ago (April 1, 2011) |
@article{Renner_2011, title={Recent Trends and Observations in the Design of High-Quality Screening Collections}, volume={3}, ISSN={1756-8927}, url={http://dx.doi.org/10.4155/fmc.11.15}, DOI={10.4155/fmc.11.15}, number={6}, journal={Future Medicinal Chemistry}, publisher={Informa UK Limited}, author={Renner, Steffen and Popov, Maxim and Schuffenhauer, Ansgar and Roth, Hans-Joerg and Breitenstein, Werner and Marzinzik, Andreas and Lewis, Ian and Krastel, Philipp and Nigsch, Florian and Jenkins, Jeremy and Jacoby, Edgar}, year={2011}, month=apr, pages={751–766} }